Gao L, Zhao F-L, Li S-C
Discipline of Pharmacy & Experimental Pharmacology, School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, Australia.
Exp Clin Endocrinol Diabetes. 2012 Jun;120(6):367-75. doi: 10.1055/s-0032-1304619. Epub 2012 May 25.
To date no consensus has been reached on whether to administer statin to patients with Polycystic Ovary Syndrome (PCOS) routinely. Therefore, we conduct a meta-analysis to synthesize the literatures regarding therapeutic effects of statins on PCOS.
A comprehensive literature search was performed using terms such as polycystic ovary syndrome, ovary polycystic disease, PCOS, hyperandrogaenemia; simvastatin, atorvastatin, lipidemic-modulating drugs, lipid lowering drugs, and testosterone; randomized controlled trials in the following bibliographic databases: Medline, Embase, Cochrane Controlled Trials Register. Identified reference lists were checked manually.
In total, 4 RCTs were included. 3 of 4 studies were double-blinded while none reported whether of the data was analyzed using intention-to-treat analysis. Serum total testosterone and lipid profiles were included as investigation outcomes. Differences in reducing serum total testosterone were observed when comparing statin with placebo (Std MD= - 3.03, 95%CI - 5.85 ~ - 0.22, P=0.03) or statin + metformin with metformin (Std MD=- 1.07, 95%CI: - 2.06~ - 0.07, P=0.04). Heterogeneities were detected in both comparisons (I2=96% and 88% respectively). Meanwhile, statin was more effective than placebo in reducing LDL (WMD=- 0.87, 95%CI - 1.18~ - 0.55, P<0.0001), TC (WMD=- 1.23 95%CI - 1.35~ - 1.11, P<0.00001), TG (WMD= - 0.50, 95%CI - 0.73~ - 0.27, P<0.00001); and statin + metformin was more effective than metformin in lowering LDL (WMD= - 0.84, 95%CI: - 1.33 ~ - 0.354, P=0.0009), TC (WMD= - 1.28, 95%CI: - 1.47 ~ - 1.10, P<0.00001), and TG (WMD= - 0.27, 95%CI: - 0.36~ - 0.19, P<0.00001). Heterogeneities were detected during the meta-analysis.
Statins can reduce the concentration of total testosterone, TC, TG and LDL. However, it cannot be concluded that statins have long-term benefit. A large-scale, randomized controlled study is needed to ascertain this uncertainty.
迄今为止,对于是否常规给予多囊卵巢综合征(PCOS)患者他汀类药物尚未达成共识。因此,我们进行一项荟萃分析以综合有关他汀类药物对PCOS治疗效果的文献。
使用多囊卵巢综合征、卵巢多囊性疾病、PCOS、高雄激素血症;辛伐他汀、阿托伐他汀、调脂药物、降脂药物以及睾酮等术语,在以下文献数据库中进行全面的文献检索:医学文献数据库(Medline)、荷兰医学文摘数据库(Embase)、Cochrane对照试验注册库。对识别出的参考文献列表进行手动检查。
总共纳入4项随机对照试验(RCT)。4项研究中有3项为双盲试验,且均未报告是否采用意向性分析对数据进行分析。血清总睾酮和血脂谱被纳入研究结局。比较他汀类药物与安慰剂时,在降低血清总睾酮方面观察到差异(标准化均数差[Std MD]= - 3.03,95%置信区间[CI] - 5.85至 - 0.22,P = 0.03);比较他汀类药物+二甲双胍与二甲双胍时,差异也显著(Std MD = - 1.07,95%CI: - 2.06至 - 0.07,P = 0.04)。两项比较中均检测到异质性(I²分别为96%和88%)。同时,他汀类药物在降低低密度脂蛋白(LDL)方面比安慰剂更有效(加权均数差[WMD]= - 0.87,95%CI - 1.18至 - 0.55,P < 0.0001),在降低总胆固醇(TC)方面也更有效(WMD = - 1.